Abstracts tagged "Drug toxicity"

Abstract Number: 1068 • ACR Convergence 2023
Multidisciplinary Prospective Study of Patients Treated with Immune Checkpoint Inhibitors Who Developed Rheumatic Immune-related Adverse Events
Mª Carmen López-González¹, Natividad Martínez Banaclocha², Montserrat García Araque², Yoel Montoyo Pujol² and Mariano Andrés³, ¹General University Hospital Dr. Balmis, Alacante, Spain, ²General University Hospital Dr. Balmis, Alicante, Spain, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain
Background/Purpose: Immune checkpoint inhibitors (ICIs), by activating the immune system (specifically, T-cells), foster the reaction against tumor cells. However, parallelly, autoimmune phenomena, known as immune-…
Abstract Number: 1070 • ACR Convergence 2023
Safety of DMARDs in Rheumatologic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: Data from a Monocentric Cohort in Hospices Civils De Lyon
Julien Seiller¹, Emmanuel Massy², Julien Peron³ and Cyrille Confavreux², ¹Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, Lyon, France, ²Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, ³Service d’oncologie médicale. Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Université de Lyon, INSERM U1290, Lyon, France
Background/Purpose: Since Immune Checkpoint Inhibitors (ICI) revolution, oncologists face immune-related adverse events (irAEs) including rheumatologic irAEs with inflammatory arthritis. Treatment of rheumatologic irAE can be…
Abstract Number: 1072 • ACR Convergence 2023
Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors
Maria Suarez-Almazor¹, Carrie Ye², Bo Zhao³, Juan Ruiz³, Hui Zhao³, Noha Abdel-Wahab⁴ and William Leslie⁵, ¹MD Anderson Cancer Center, Houston, TX, ²University of Alberta, Edmonton, AB, Canada, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, Houston, TX, ⁵University of Manitoba, Internal Medicine, Winnipeg, MB, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. Despite their efficacy on tumor outcomes they can cause severe and sometimes long-standing immune-related…
Abstract Number: 1080 • ACR Convergence 2023
Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study
Antoine Minier¹, Gilles Boire¹, Sophie ROUX¹, Nathalie Carrier² and Hugues Allard-Chamard¹, ¹Université de Sherbrooke, Sherbrooke, QC, Canada, ²CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada
Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) are used to treat a variety of inflammatory conditions ranging from rheumatoid arthritis to sarcoidosis. Paradoxical side-effects (PSE)…
Abstract Number: 0347 • ACR Convergence 2023
Towards Effective Shared Decision Making – Development and Validation of a Prediction Model for Personalized Probabilities of Side Effects in the Initial Treatment of Juvenile Idiopathic Arthritis
Jonathan Park¹, Thomas Loughin², Andrew Henrey² and Jaime Guzman³, ¹Western University, London, ON, Canada, ²British Columbia Children's Hospital, Vancouver, BC, Canada, ³British Columbia Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Clinical practice guidelines for Juvenile Idiopathic Arthritis (JIA) emphasize the importance of adapting guideline recommendations to each individual patient through shared decision-making among patients,…
Abstract Number: 1096 • ACR Convergence 2023
A Quality Improvement Project About Medication Adherence to Understand What Questions Rheumatology Patients Have About Their Medications, and How They Answer Them
Lena Eder¹, Kai Sun², Sonali Bracken³, Ann Cameron Barr⁴, Jeffrey Shen⁴, Dahima Cintron⁴, Mithu Maheswaranathan⁴, Catherine Sims², Poorva Apte⁴, Megan Milne⁵, Nathaniel Harris⁴ and David Leverenz⁶, ¹Duke University, Chapel Hill, NC, ²Duke University, Durham, NC, ³Duke University Hospital, Apex, NC, ⁴Duke University Hospital, Durham, NC, ⁵Costal Carolina Health Care, New Bern, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: Medication non-adherence remains high among rheumatology patients, yet little is known about adherence barriers faced by patients or interventions that improve adherence. As part…
Abstract Number: 0355 • ACR Convergence 2023
Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis
Ana Isabel Rebollo Gimenez¹, Luca Carlini², Paivi Miettunen³, Ekaterina Alexeeva⁴, Charlotte Myrup⁵, Rebecca Nicolai⁶, Maria Trachana⁷, Valda Stenevicha⁸, Constantin Ailioaie⁹, Elena Tsitsami¹⁰, Alexis-Virgil Cochino¹¹, Chiara Pallotti¹², Silvia Scala¹², Angela Pistorio¹³, Sebastiaan Vastert¹⁴, Joost Swart¹⁵ and Nicolino Ruperto¹⁶, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, ³University of Calgary and Alberta Children’s Hospital, Calgary, AB, Canada, ⁴Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁵Pediatric rheumatology unit 4272, Rigshospitalet, Copenhagen, Denmark, ⁶Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁷First Department of pediatrics, Pediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Thessaloniki University School of Medicine, Thessaloniki, Greece, ⁸Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, ⁹Pediatric Rheumatology , Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ¹⁰Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children's Hospital "Aghia Sophia", University of Athens, Athens, Greece, ¹¹First Department of Pediatrics, University of Athens Medical School, Aghia Sophia Childrens Hospital, Athens, Greece, ¹²Pediatric and Rheumatology Clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹³Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹⁴University Medical Center Utrecht, Utrecht, Netherlands, ¹⁵Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, ¹⁶IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy
Background/Purpose: Evidence on treatment safety in systemic juvenile idiopathic arthritis (sJIA) is limited. Our objective was to evaluate the safety profile of drugs in the…
Abstract Number: 1111 • ACR Convergence 2023
Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis
Palapun Waitayangkoon¹, Tatchaya Kanthajan² and Thiratest Leesutipornchai³, ¹MetroWest Medical Center, Framingham, MA, ²Srinakharinwirot University, Bangkok, Thailand, ³University of Hawaii, Honolulu, HI
Background/Purpose: Recent studies have suggested that hyperuricemia is significantly associated with an increased prevalence of atrial and ventricular arrhythmias and urate-lowering therapy (ULT) may provide…
Abstract Number: 0449 • ACR Convergence 2023
Parsing Pathophysiology of Rheumatoid Arthritis-associated Lymphoproliferative Disorders via Whole RNA Transcriptome Analysis: Multi-center Study in Japan
ATSUKO TSUJII¹, KAZUKO SAKAI², SHIRO OHSHIMA¹, YUKIHIKO SAEKI¹, MASATO YAGITA³, TOMOYA MIYAMURA⁴, Masao Katayama⁵, YASUSHI HIRAMATSU⁶, SHINJI HIGA⁷, FUMINORI HIRANO⁸, KENJI ICHIKAWA⁹, NORIYUKI CHIBA¹⁰, TAKAO SUGIYAMA¹¹, ATSUSHI IHATA¹², HIROSHI TSUTANI¹³, KOICHIRO TAKAHI¹⁴, KIYOSHI MIGITA¹⁵, SHUNSUKE MORI¹⁶, NORIE YOSHIKAWA¹⁷, ATSUHISA UEDA¹⁸, SHOUHEI NAGAOKA¹⁹, KEIGO SETOGUCHI²⁰, SHOJI SUGII²¹, ASAMI ABE²², TOSHIAKI SUGAYA²³, HIROYUKI SUGAHARA²⁴, SHINICHIRO TSUNODA²⁴, NORISHIGE IIZUKA²⁵, RYOSUKE YOSHIHARA²⁶, HIROKI YABE²⁷, TOMOAKI FUJISAKI²⁸, EIICHI MORII²⁹, KAZUYOSHI SAITO³⁰, Kiyoshi Matsui³¹, YASUHIKO TOMITA³², HIROSHI FURUKAWA³³, Shigeto Tohma³⁴, KAZUTO NISHIO² and YOSHIHIKO HOSHIDA³⁵, ¹National Hospital Organization (NHO), Osaka Minami Medical Center, Kawachinagano, Japan, ²Kindai University School of Medicine Department of Genome Biology, Sayama, Japan, ³Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan, ⁴NHO Kyushu Medical Center, Fukuoka, Japan, ⁵National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, ⁶Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁷Daini Osaka Police Hospital, Osaka, Japan, ⁸NHO Asahikawa Medical Center, Asahikawa, Japan, ⁹Nissei hospital, Sapporo, Japan, ¹⁰NHO Morioka Medical Center, Morioka, Japan, ¹¹NHO Shimoshizu Hospital, Yotsukaido, Japan, ¹²NHO Yokohama Medical Center, Yokohama, Japan, ¹³NHO Awara Hospital, Awara, Japan, ¹⁴NHO Osaka Toneyama Medical Center, Toyonaka, Japan, ¹⁵Department of Rheumatology Fukushima Medical University School of Medicine, Fukushima, Japan, ¹⁶NHO Kumamoto Saishun Medical Center, Koshi, Japan, ¹⁷NHO Miyakonojo Medical Center, Miyakonojo, Japan, ¹⁸Yokohama City University Medical Center, Yokohama, Japan, ¹⁹Yokohama Minami Kyosai Hospital, Yokohama, Japan, ²⁰Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital / Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, ²¹Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, ²²Niigata Rheumatic Center, Shibata, Japan, ²³Fuchu Hospital, Izumi, Japan, ²⁴Sumitomo Hospital, Osaka, Japan, ²⁵Kishiwada City Hospital, Kishiwada, Japan, ²⁶Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, ²⁷Ako Central Hospital, Ako, Japan, ²⁸Matsuyama Red Cross Hospital, Matsuyama, Japan, ²⁹Osaka University, Suita, Japan, ³⁰University of Occupational and Environmental Health, Kitakyushu, Japan, ³¹Hyogo Medical University, Nishinomiya, Japan, ³²International University of Health and Welfare, Otawara City, Japan, ³³NHO Tokyo National Hospital, Kiyose, Japan, ³⁴NHO Tokyo National Hospital, Dallas, TX, ³⁵National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan
Background/Purpose: Lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) have unique pathophysiological features. More than half of the cases of RA-LPD undergo spontaneous regression after…
Abstract Number: 1317 • ACR Convergence 2023
Discontinuation of Biological Disease Modifying Drugs Due to Adverse Drug Reactions in an Inception Rheumatoid Arthritis Cohort
Zulema Rosales-Rosado¹, Maria Rodriguez Laguna², Cristina lajas Petisco², Clara De Miguel² and lydia Abasolo¹, ¹Hospital Clínico San Carlos, Madrid, Spain, ²Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the use of Disease Modifying Drugs (DMARD).…
Abstract Number: 0462 • ACR Convergence 2023
Breastfeeding Intention in Systemic Lupus Erythematosus Patients
Susana Villamizar Pérez¹, Nicole Josianne Paris¹, Melissa Serna Góngora¹, Ariel Brener¹, Jerson Claros¹, Maria Pia Izaguirre Germain¹, Barbara Pérez Cepas², Marina Micelli³, Gabriel Sequeira¹ and Eduardo Mario Kerzberg¹, ¹Hospital Dr. JM Ramos Mejia, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital medico policial Churruca Visca, Ciudad Autonoma de Buenos Aires, Argentina, ³RELESSAR, CABA, Argentina
Background/Purpose: Breastfeeding in systemic lupus erythematosus (SLE) has received little attention and the limited data available suggest that women with SLE have lower breastfeeding rates…
Abstract Number: 1333 • ACR Convergence 2023
Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset
YOSHIHIKO HOSHIDA¹, Atsuko Tsujii², SHIRO OHSHIMA³, YUKIHIKO SAEKI³, MASATO YAGITA⁴, TOMOYA MIYAMURA⁵, Masao Katayama⁶, TOMONORI KAWASAKI⁷, YASUSHI HIRAMATSU⁸, Hisaji Oshima⁹, TOSHIHIKO MURAYAMA¹⁰, SHINJI HIGA¹¹, KAZUYA KURAOKA¹², FUMINORI HIRANO¹³, KENJI ICHIKAWA¹⁴, MITSUTOSHI KUROSAWA¹⁵, HIROAKI SUZUKI¹⁵, NORIYUKI CHIBA¹⁶, TAKAO SUGIYAMA¹⁷, YUKO MINAMI¹⁸, HITOSHI NIINO¹⁹, ATSUSHI IHATA²⁰, IKUO SAITO²¹, AKIKO MITSUO²², TOSHITAKA MAEJIMA²³, ATSUHIRO KAWASHIMA²⁴, HIROSHI TSUTANI²⁵, KOICHIRO TAKAHI²⁶, TAKAHIKO KASAI²⁷, YOKO SHINNO²⁸, YOSHIRO TACHIYAMA²⁹, NORIHIRO TERAMOTO³⁰, KENICHI TAGUCHI³¹, SHINJI NAITO³², SHIGERU YOSHIZAWA³³, MASAHIRO ITO³⁴, YASUO SUENAGA³⁵, Shunsuke Mori³⁶, SHOICHI NAGAKURA³⁷, NORIE YOSHIKAWA³⁸, MITSUHARU NOMOTO³⁹, ATSUHISA UEDA⁴⁰, SHOUHEI NAGAOKA⁴¹, YUKIO TSUURA⁴², KEIGO SETOGUCHI⁴³, SHOJI SUGII⁴⁴, Asami Abe⁴⁵, TOSHIAKI SUGAYA⁴⁶, HIROYUKI SUGAHARA⁴⁷, MASAHIRO KOSETO⁴⁸, YASUO KUNUGIZA², NORISHIGE IIZUKA³, RYOSUKE YOSHIHARA⁴, HIROKI YABE⁵, TOMOAKI FUJISAKI⁶, EIICHI MORII⁷, MORISHIGE TAKESHITA⁸, MASAKAZU SATO⁹, KAZUYOSHI SAITO¹⁰, Kiyoshi Matsui¹¹, YASUHIKO TOMITA¹², HIROSHI FURUKAWA¹³ and Shigeto Tohma¹⁴, ¹National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, ²Osaka Minami Medical Center, Kawachinagano City, Japan, ³National Hospital Organization (NHO), Osaka Minami Medical Center, Kawachinagano, Japan, ⁴Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan, ⁵NHO Kyushu Medical Center, Fukuoka, Japan, ⁶National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, ⁷NHO Nagoya Medical Center, Nagoya, Japan, ⁸Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁹National Tokyo Medical Center, Tokyo, Japan, ¹⁰NHO Kumamoto Medical Center, Kumamoto, Japan, ¹¹Daini Osaka Police Hospital, Osaka, Japan, ¹²NHO Kure Medical Center /Chugoku Cancer Center, Kure, Japan, ¹³NHO Asahikawa Medical Center, Asahikawa, Japan, ¹⁴Nissei hospital, Sapporo, Japan, ¹⁵NHO Hokkaido Cancer Center, Sapporo, Japan, ¹⁶NHO Morioka Medical Center, Morioka, Japan, ¹⁷NHO Shimoshizu Hospital, Yotsukaido, Japan, ¹⁸NHO Ibarakihigashi Hospital, Ibaraki, Japan, ¹⁹NHO Yokohama Medical Center, Yokohama, Japan, ²⁰National Hospital Organization Yokohama Medical Center, Yokohama, Japan, ²¹NHO Sagamihara Hospital, Sagamihara, Japan, ²²NHO Disaster Medical Center, Tachikawa, Japan, ²³NHO Shinshu Ueda Medical Center, Ueda, Japan, ²⁴NHO Kanazawa Medical Center, Kanazawa, Japan, ²⁵NHO Awara Hospital, Awara, Japan, ²⁶NHO Osaka Toneyama Medical Center, Toyonaka, Japan, ²⁷Japan Red Cross Society Tokushima Hospital, Komatsushima, Japan, ²⁸NHO Okayama Medical Center, Okayama, Japan, ²⁹NHO Hiroshima Nishi Medical Center, Otake, Japan, ³⁰NHO Shikoku Cancer Center, Matsuyama, Japan, ³¹NHO Kyushu Cancer Center, Fukuoka, Japan, ³²NHO Ureshino Medical Center, Ureshino, Japan, ³³NHO Fukuoka Hospital, Fukuoka, Japan, ³⁴NHO Nagasaki Medical Center, Omura, Japan, ³⁵NHO Beppu Medical Center, Beppu, Japan, ³⁶NHO Kumamoto Saishun Medical Center, Koshi, Japan, ³⁷NHO Kumamoto Minami Hospital, Uki, Japan, ³⁸NHO Miyakonojo Medical Center, Miyakonojo, Japan, ³⁹NHO Kagoshima Medical Center, Kagoshima, Japan, ⁴⁰Yokohama City University Medical Center, Yokohama, Japan, ⁴¹Yokohama Minami Kyosai Hospital, Yokohama, Japan, ⁴²Department of Pathology Yokosuka Kyosai Hospital, Yokosuka, Japan, ⁴³Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital / Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, ⁴⁴Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, ⁴⁵Niigata Rheumatic Center, Shibata, Japan, ⁴⁶Fuchu Hospital, Izumi, Japan, ⁴⁷Sumitomo Hospital, Osaka, Japan, ⁴⁸Nippon Life Hospital, Osaka, Japan, ⁴⁹JCHO Hoshigaoka Medical Center, Hirakata, Japan, ⁵⁰Kishiwada City Hospital, Kishiwada, Japan, ⁵¹Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, ⁵²Ako Central Hospital, Ako, Japan, ⁵³Matsuyama Red Cross Hospital, Matsuyama, Japan, ⁵⁴Osaka University, Suita, Japan, ⁵⁵Fukuoka University, Fukuoka, Japan, ⁵⁶Kurashiki University of Science and the Arts, Kurashiki, Japan, ⁵⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵⁸Hyogo Medical University, Nishinomiya, Japan, ⁵⁹International University of Health and Welfare, Otawara City, Japan, ⁶⁰NHO Tokyo National Hospital, Kiyose, Japan, ⁶¹NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: The largest multi-center collaborative study on lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) in Japan was conducted to characterize its clinical outcomes and…
Abstract Number: 0741 • ACR Convergence 2023
Adverse Events Among Patients with and Without Autoimmune Rheumatic Disease Prescribed SGLT2 Inhibitors
Emily G. Oakes¹, Jack Ellrodt¹, May Choi², Jeong Yee¹, Hongshu Guan¹ and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Sodium glucose cotransporter 2 inhibitors (SGLT2i) are oral hypoglycemic agents for Type II diabetes mellitus (T2D) now prescribed for renal and cardiovascular indications. Patients…
Abstract Number: 1362 • ACR Convergence 2023
Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs
Rina Ferguson¹, Itay Marmor² and Maleewan Kitcharoensakkul¹, ¹Washington University/B-JH/SLCH Consortium, St. Louis, MO, ²Dana-Dwek Children's Hospital, Hod Hasharon, Israel
Background/Purpose: Several rheumatologic medications routinely prescribed to adolescent females are teratogenic. However, there is no standard method to educate our patients and their families about…
Abstract Number: 1014 • ACR Convergence 2023
Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy and Subsequent Referrals to Rheumatologists at a Private vs Public Medical Center in Los Angeles: Ramifications for Health Disparities
Laura Kobashigawa¹, Nicole Zagelbaum², Katherine Ruddy³, Martha Delgado¹, Baljeet Rai⁴, Victoria Gevorgyan⁵, Kiana Mortezaei⁶, William Stohl⁷ and Elizabeth Taylor-Albert MD⁸, ¹LAC+USC Internal Medicine Residency, Los Angeles, CA, ²Beverly Hills Arthritis Associates, Beverly Hills, CA, ³LAC+USC Internal Medicine Residency, Los Angeles, MD, ⁴University of California San Francisco, San Francisco, CA, ⁵Los Angeles County Hospital, Los Angeles, CA, ⁶Keck Medical Center of USC, Los Angeles, CA, ⁷University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, ⁸University of Southern California, Santa Monica, CA
Background/Purpose: Immune checkpoint inhibitors (ICIs) represent a breakthrough in cancer therapies. However, ICIs may be associated with significant immune-related adverse events (irAEs), including rheumatic irAEs.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].